How Long Can You Stay on HRT? What the Guidelines Actually Say

From a misunderstanding of the Women's Health Initiative that has proven remarkably hard to kill.

The WHI was a large randomized trial that began enrolling in the 1990s. Its estrogen-plus-progestin arm was stopped early in 2002, after an average follow-up of about 5.2 years, because a monitoring board judged that overall risks exceeded benefits in the population studied. Media coverage was extensive and alarming, and prescriptions for hormone therapy collapsed worldwide within months.

Here is the key point: 5.2 years was how long the trial ran before it was stopped. It was never a recommended treatment duration. But in the confusion that followed, "the trial was stopped at five years" became "you should stop at five years," and that mutation embedded itself in clinical practice and patient understanding for two decades.

There was a second, larger misreading. The WHI enrolled women whose average age was 63, more than a decade past the typical age of menopause, and many had been without estrogen for years. That population is not representative of the woman who starts hormone therapy at 51 for disruptive hot flashes. Subsequent reanalyses showed the risk profile differs substantially depending on age at initiation and time since menopause — the basis of what is now called the [timing hypothesis](/blog/when-to-start-hrt-the-timing-hypothesis-explained).

So the five-year rule was doubly wrong: wrong about what the number meant, and derived from a population most women seeking treatment do not resemble. Understanding this is what makes the current guidance make sense.

Individualized treatment with periodic reassessment — and explicitly no arbitrary limits.

The 2022 Hormone Therapy Position Statement of The North American Menopause Society (now The Menopause Society) is the reference document most clinicians in the US work from. On duration, its position is direct: treatment should be individualized using the best available evidence to maximize benefits and minimize risks, with periodic reevaluation of the benefits and risks of continuing.

It goes further on the age question. The statement notes that women older than 65 can continue using hormone therapy with appropriate counselling and risk assessment, rather than treating 65 as a cutoff. It also states that longer durations are appropriate for documented indications — persistent bothersome vasomotor symptoms being the most common — through shared decision-making.

The favourable window is described in terms of when you *start*, not how long you continue. For women younger than 60, or within 10 years of menopause onset, without contraindications, the benefit-risk ratio is favourable for treating bothersome hot flashes and night sweats and for preventing bone loss.

What "periodic reevaluation" means in practice is an annual conversation: are your symptoms still present if you were to stop, has your personal or family risk profile changed, is the route and dose still right, and are you due for screening. It is not a countdown clock. It is the same kind of ongoing review that applies to blood pressure medication or a statin.

Some risks are duration-related, some are not, and the specific formulation matters more than most people realize.

The risk that does relate to duration is breast cancer with combined estrogen-plus-progestogen therapy. The WHI found no increase in the first several years of use, with a small increase emerging with longer duration. In absolute terms this is often described as fewer than one additional case per 1,000 women per year of use in the WHI population — comparable in magnitude to risk associated with drinking one to two alcoholic drinks daily, or with obesity, or with physical inactivity. Notably, the estrogen-only arm of the WHI, given to women who had had a hysterectomy, did not show an increase in breast cancer, and some analyses found a reduction.

Route of administration changes the picture for clot risk. Oral estrogen passes through the liver first and increases clotting factor production, raising the risk of venous thromboembolism and stroke. Transdermal estrogen — patch, gel, or spray — largely bypasses this and observational data suggest it does not carry the same clot risk. This is one reason many clinicians favour transdermal delivery for longer-term use, especially with other risk factors; our comparison of [patch versus pill versus gel](/blog/hrt-patch-vs-pill-vs-gel-which-is-safest) goes through the differences.

On the benefit side, some effects also depend on continuation. Bone protection is one of them: bone density gains are not permanent, and bone loss resumes when hormone therapy stops. That is a genuine consideration for women who continue primarily for skeletal reasons, alongside the other measures in our guide to [osteoporosis prevention](/blog/osteoporosis-prevention-in-menopause-what-actually-works).

No. It is a point at which the conversation should be revisited more carefully — not a stop sign.

The 65 threshold entered common practice partly through prescribing guidance such as the Beers Criteria, which flags certain medications as potentially inappropriate in older adults, and partly through general caution about the WHI findings in older women. It has often been applied more rigidly than intended.

The Menopause Society's position is that women over 65 may continue hormone therapy with appropriate counselling and periodic risk assessment. What changes after 65 is not permission but context: baseline cardiovascular risk, stroke risk, and breast cancer risk all rise with age independent of hormone therapy, so the same relative risk translates into a larger absolute number of events. That is a real consideration, and it is why the conversation deserves more care rather than less.

In practice, women who continue past 65 often do so for one of three reasons: hot flashes that genuinely have not stopped (and for a meaningful minority of women, vasomotor symptoms persist into their late 60s and beyond), bone protection where other options are unsuitable, or quality of life effects they are unwilling to give up. Many clinicians will move toward the lowest effective dose and a transdermal route in this situation.

Worth separating out entirely: vaginal estrogen. Low-dose local estrogen for genitourinary symptoms has minimal systemic absorption, is not subject to the same duration considerations, and is generally continued indefinitely because symptoms recur when it stops. Our guide to [vaginal estrogen](/blog/vaginal-estrogen-local-hrt-for-dryness-and-utis) covers why it sits in a different category.

The only way to find out is a trial of stopping — but how you stop changes what you learn.

There are two approaches. Tapering — gradually reducing dose over several months — is the more common recommendation, on the reasoning that it lets you distinguish returning symptoms from a temporary rebound and gives you the option to stop the taper if symptoms flare. Abrupt discontinuation gives a faster answer but a harsher one. The evidence comparing the two is limited and does not strongly favour either for long-term symptom outcomes.

What to expect if you stop: hot flashes return in a substantial proportion of women, sometimes within weeks. This is not a sign of dependence or withdrawal in any addictive sense — it means the underlying vasomotor instability had not yet resolved on its own, and the hormone therapy had been controlling it. If symptoms return severely, restarting is a legitimate choice, not a failure.

Give it enough time before concluding. Symptoms often spike in the first 4 to 8 weeks and then settle, so stopping in December and judging in January may mislead you. Three to six months is a fairer test.

Timing helps. Do not attempt a stop during a period of high stress, poor sleep, or major life change, because you will not be able to separate the variables. And track it — a simple daily record of hot flash frequency, sleep quality, and mood gives you real data to bring to the follow-up conversation rather than an impression.

If symptoms return and you would rather not resume hormones, there are now genuinely effective [non-hormonal options for hot flashes](/blog/veozah-fezolinetant-nonhormonal-hot-flash-treatment-explained) that did not exist a few years ago.

Go in with specific questions, because a vague appointment tends to produce a vague answer — often the default "you've been on it a while, maybe it's time to come off."

Ask what my specific risk profile is, not the population average. Your family history of breast cancer, your cardiovascular risk factors, your bone density, your clotting history, and your body weight all shift the calculation. A woman with osteopenia and no family history of breast cancer is in a different position from one with the reverse.

Ask whether the route and dose are still right. Someone who started on an oral preparation at 51 may be a better candidate for transdermal at 62, and dose requirements often fall over time. This is one of the most useful and least-discussed adjustments.

Ask which progestogen you are on and why, if you have a uterus. Micronized progesterone and various synthetic progestins differ in their effects, and the choice is not always revisited after it is first made — our guide to [progesterone in menopause](/blog/progesterone-in-menopause-what-it-does-and-why-you-need-it) explains what differs.

Ask what would make you recommend I stop. This turns an open-ended anxiety into a concrete set of conditions you can both monitor.

And ask what my plan is if I stop and symptoms return. Knowing there is a route back — either restarting or a non-hormonal alternative — makes a trial of stopping much less daunting.

One broader note: menopause care is variable, and many clinicians received limited training in it. If your questions are being dismissed rather than answered, seeking out a clinician with specific menopause expertise is reasonable, not demanding.